X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Panacea Biotech with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs MYLAN (US) - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PANACEA BIOTECH   MYLAN
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
MYLAN
Dec-14
PANACEA BIOTECH/
MYLAN
5-Yr Chart
Click to enlarge
High Rs1493,824-   
Low Rs822,695-   
Sales per share (Unadj.) Rs84.11,309.1-  
Earnings per share (Unadj.) Rs-18.3157.7-  
Cash flow per share (Unadj.) Rs-6.7253.8-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs83.7650.7-  
Shares outstanding (eoy) m61.25378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x1.42.5 55.1%   
Avg P/E ratio x-6.320.7 -30.5%  
P/CF ratio (eoy) x-17.212.8 -134.3%  
Price / Book Value ratio x1.45.0 27.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m7,0741,233,232 0.6%   
No. of employees `0002.825.0 11.0%   
Total wages/salary Rs m1,4490-   
Avg. sales/employee Rs Th1,874.119,812.6 9.5%   
Avg. wages/employee Rs Th527.00-   
Avg. net profit/employee Rs Th-407.72,386.8 -17.1%   
INCOME DATA
Net Sales Rs m5,154495,315 1.0%  
Other income Rs m100-2,887 -3.5%   
Total revenues Rs m5,254492,428 1.1%   
Gross profit Rs m-766123,187 -0.6%  
Depreciation Rs m71136,379 2.0%   
Interest Rs m1,50321,365 7.0%   
Profit before tax Rs m-2,88162,556 -4.6%   
Minority Interest Rs m11-257 -4.2%   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m172,631 0.6%   
Profit after tax Rs m-1,12159,669 -1.9%  
Gross profit margin %-14.924.9 -59.8%  
Effective tax rate %-0.64.2 -13.9%   
Net profit margin %-21.812.0 -180.6%  
BALANCE SHEET DATA
Current assets Rs m3,810435,448 0.9%   
Current liabilities Rs m8,365340,433 2.5%   
Net working cap to sales %-88.419.2 -460.8%  
Current ratio x0.51.3 35.6%  
Inventory Days Days15678 199.4%  
Debtors Days Days67107 62.7%  
Net fixed assets Rs m14,480114,590 12.6%   
Share capital Rs m6117,516 0.3%   
"Free" reserves Rs m9030-   
Net worth Rs m5,127246,220 2.1%   
Long term debt Rs m5,832367,829 1.6%   
Total assets Rs m19,433991,753 2.0%  
Interest coverage x-0.93.9 -23.3%   
Debt to equity ratio x1.11.5 76.1%  
Sales to assets ratio x0.30.5 53.1%   
Return on assets %2.08.2 24.0%  
Return on equity %-21.924.2 -90.2%  
Return on capital %3.613.6 26.7%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Net fx Rs m5970-   
CASH FLOW
From Operations Rs m59965,110 0.9%  
From Investments Rs m-438-51,347 0.9%  
From Financial Activity Rs m-303-17,156 1.8%  
Net Cashflow Rs m-141-3,394 4.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.16 Rs / USD

Compare PANACEA BIOTECH With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  

Compare PANACEA BIOTECH With: DISHMAN PHARMA  ALEMBIC LTD  UNICHEM LAB  CIPLA  GLENMARK PHARMA  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views On News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Aug 18, 2017 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS